The market for PARP inhibitors, a cornerstone in targeted cancer treatment, is projected to more than triple from $3 billion in 2022 to an estimated $10.3 billion by 2031.
Stay Updated! Subscribe to The Primer
Share
Beating the Odds: Next-Gen Therapies in Heart Disease
Discover the latest treatments for heart disease. From generic competition to innovative solutions, find out how the industry is evolving.
Swallowing a Biologic Drug?
Biological drugs — composed of proteins produced by living cells — have become some of the safest, most effective therapeutics in the pharmaceutical industry.
Breaking Down Drug Metabolism in Drug Development
Understand the process of drug metabolism and how our bodies respond to medication at a cellular level.
The Global Regulatory Landscape
Learn about the global regulatory process when bringing new medications to the market, from the FDA to other governing bodies.
Exploring Epigenetic DNA Modifications
Epigenetics refers to the study of changes in gene activity that occur without altering the underlying DNA sequence. Epigenetic changes…
Explore the Potential of Peptide Therapies
The market for peptide therapies is rapidly becoming a pivotal area in precision medicine.
From Drug Discovery to Approval: Phase IV
We previously focused on the final stage of clinical testing, Phase III trials, where drug developers assess the safety and efficacy of their drug in large patient groups. At the end of Phase III, drug developers face the moment of truth: does the study data support...
From Drug Discovery to Approval: Phase III
Our recent article explored the riskiest part of the human clinical trials pathway: Phase II. About 70% of drugs that enter Phase II never make it out. Most often, it’s because they fail to demonstrate effectiveness. Even making it to Phase III is no guarantee of...
From Drug Discovery to Approval: Phase I/II
Every drug in clinical use today, from the latest CAR-T treatment to older cholesterol-lowering statins, share one thing in common: they have all successfully navigated the rigorous clinical trials process. This is no small feat, as only ~10% of the drugs that enter...
Biotech Primer is your go-to source for interactive training across the biotechnology, pharmaceutical, molecular diagnostics, and medical device sectors. Explore a range of in-depth biotech courses designed to deepen your understanding of key principles and applications in the field.